Navigation Links
HIV Meds May Also Help Control Hepatitis C, Study Finds
Date:7/23/2014

WEDNESDAY, July 23, 2014 (HealthDay News) -- For patients infected with both HIV and hepatitis C, HIV antiretroviral therapy may help control both viruses, a small study suggests.

Researchers said doctors could use their findings to improve treatment strategies for people with the two diseases.

"The findings suggest that HIV suppression with antiretroviral medications plays an important role in the management of individuals with [hepatitis C] and HIV infection," said study leader Dr. Kenneth Sherman, a professor of medicine at the University of Cincinnati College of Medicine. "It supports the concept that in those with HCV/HIV infection, early and uninterrupted HIV therapy is a critical part of preventing liver disease."

The researchers conducted the study to address concerns that treating patients who have HIV -- the AIDS-causing virus -- and hepatitis C with HIV antiretroviral therapy would damage the liver and cause more harm than good.

To put this theory to the test, they closely examined 17 patients infected with both viruses for two years. The patients received approved HIV antiretroviral drugs. They were also examined frequently, and their blood was routinely tested to track any changes in the viruses and their immune response.

The findings were published July 23 in the journal Science Translational Medicine.

Some patients experienced an initial increase in a blood test that shows changes in liver injury, hepatitis C or both in the first 16 weeks of the study.

Over 18 months, however, the study revealed that "viral loads" for hepatitis C dropped back down to levels expected for a patient infected with only hepatitis C and not HIV.

"The drop in [hepatitis C] viral levels was a big surprise, and not what we necessarily expected," said Sherman in a university news release. "There is a complex interaction of biological effects when patients are infected with both HIV and the hepatitis C virus." He explained that initially HIV treatment results in a transient increase in hepatitis C viral replication and evidence of liver injury. However, over time, HIV suppression leads to reduced hepatitis C viral replication.

In the United States, up to 300,000 people are infected with both hepatitis C and HIV. Globally, that number increases to between 4 million and 8 million, the researchers said.

Drug makers Bristol-Myers Squibb and Gilead Sciences supplied the antiretroviral medications used in the study at no charge. One of the scientists involved in the research, Dr. Judith Feinberg, a professor of infectious diseases at the University of Cincinnati, is a Bristol-Myers Squibb investigator and speaker.

More information

The U.S. Department of Health and Human Services provides more information on antiretroviral therapy.

SOURCE: University of Cincinnati Academic Health Center, news release, July 23, 2014

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Controlling childbirth pain tied to lower depression risk
2. Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports
3. Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC
4. SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control
5. Faithful cell division requires tightly controlled protein placement at the centromeres
6. Xarelto is Alleged to Cause Serious and Uncontrolled Internal Bleeding
7. Study: Robot-assisted surgery for prostate cancer controls the disease for 10 years
8. New combination drug controls tumor growth and metastasis in mice
9. Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department
10. Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts
11. Controlling movement with light
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HIV Meds May Also Help Control Hepatitis C, Study Finds
(Date:1/24/2017)... ... January 24, 2017 , ... ... eliminate cyber threats in real-time, today announced a strategic partnership with Paramount ... to monitor, respond and protect their critical information assets and infrastructure, in a ...
(Date:1/24/2017)... ... ... Bellus Medical, a leader in medical aesthetics, today announced that Marek Dobke, M.D., ... will provide physician oversight for in-house clinical studies and hands-on device training, among other ... Professor of Surgery at UC San Diego Health and is a board certified plastic ...
(Date:1/24/2017)... ... 24, 2017 , ... The University of Iowa, long recognized as one of ... program that provides teachers with the specific skills and training they need to teach ... for post-baccalaureate students and HigherEducation.com is working to ensure that this new program is ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Allied Market Research, titled, "Cold Chain Logistics Market by ... & Frozen Dessert, Meat, Fish & Sea Food, Drugs ... Industry Forecasts, 2014-2022," projects that the global cold chain ... 2022, growing at a CAGR of 16% (2016 to ...
(Date:1/24/2017)... January 24, 2017 Analysis of the Liquid ... Liquid Biopsies - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover How ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017 /PRNewswire/ ... leader in the engineering and industrialization of biology to improve ... announced that it has entered into a definitive agreement to ... a clinical-stage company and pioneer in the development of AdenoVerse™ ... and expand upon GenVec,s expertise in adenoviral vectors and cGMP ...
Breaking Medicine Technology: